SIMCER was a 6-mo, multicenter, open-label trial. Selected de novo liver transplant recipients were randomized (week 4) to everolimus with low-exposure tacrolimus discontinued by month 4 (n = 93) or to tacrolimus-based therapy (n = 95), both with basiliximab induction and enteric-coated mycophenolate sodium with or without steroids. The primary end point, change in estimated GFR (eGFR; MDRD formula) from randomization to week 24 after transplant, was superior with everolimus (mean eGFR change +1.1 vs. À13.3 mL/min per 1.73 m 2 for everolimus vs. tacrolimus, respectively; difference 14.3 [95% confidence interval 7.3-21.3]; p < 0.001). Mean eGFR at week 24 was 95.8 versus 76.0 mL/min per 1.73 m 2 for everolimus versus tacrolimus (p < 0.001). Treatment failure (treated biopsy-proven acute rejection [BPAR; rejection activity index score >3], graft loss, or death) from randomization to week 24 was similar (everolimus 10.0%, tacrolimus 4.3%; p = 0.134). BPAR was more frequent between randomization and month 6 with everolimus (10.0% vs. 2.2%; p = 0.026); the rate of treated BPAR was 8.9% versus 2.2% (p = 0.055). Sixteen everolimus-treated patients (17.8%) and three tacrolimus-treated patients (3.2%) discontinued the study drug because of adverse events. In conclusion, early introduction of everolimus at an adequate exposure level with gradual calcineurin inhibitor (CNI) withdrawal after liver transplantation, supported by induction therapy and mycophenolic acid, is associated with a significant renal benefit versus CNI-based immunosuppression but more frequent BPAR.
Introduction
Introduction of the calcineurin inhibitor (CNI) class of immunosuppressants made a major contribution to the development of liver transplantation, tripling survival rates compared with the pre-CNI era (1) . CNI maintenance therapy, typically with tacrolimus, remains virtually universal following liver transplantation (2) . Until recently, few alternative immunosuppressive strategies were available, despite awareness of the long-term complications associated with chronic exposure to CNI therapy. The most worrying of these is progressive renal deterioration due to CNI-related nephrotoxicity (3) . An increase in cardiovascular risk factors such as new-onset diabetes mellitus (4), hypertension (5) , and hyperlipidemia (6) is also of great concern. Withdrawal of CNI therapy after the initial high-risk period early after transplantation is an appealing option if rejection prophylaxis can be adequately sustained.
Mycophenolic acid (MPA) is widely used as an adjunct to CNI therapy, often to support steroid avoidance, but conversion to MPA within a CNI-free regimen is associated with an increased risk of acute rejection (7) . The mammalian target of rapamycin (mTOR) inhibitors appear more promising for achieving long-term CNI-free maintenance therapy. Randomized trials have investigated various approaches to using the mTOR inhibitor everolimus to support CNI withdrawal after liver transplantation. The H2304 study randomized 719 de novo liver transplant patients to everolimus with tacrolimus minimization, everolimus with tacrolimus withdrawal, or a standard tacrolimus regimen (8, 9) . Everolimus was introduced at day 30 after transplant, and tacrolimus was withdrawn from month 4 over a 3-week period. The rate of biopsyproven acute rejection (BPAR) was significantly lower in the everolimus/reduced tacrolimus arm versus standard tacrolimus, but tacrolimus withdrawal resulted in a high incidence of acute rejection (26.4%), and recruitment to this group was discontinued. Renal function during the 2-year study was significantly higher in the everolimus/ reduced tacrolimus group than the control arm and was even higher in the tacrolimus withdrawal group despite the fact that more than half of the patients had reverted to CNI therapy (8, 9) . In the H2304 study, patients did not receive induction therapy, and MPA was not permitted after randomization. In contrast, the PROTECT study showed that patients given basiliximab induction with gradual early withdrawal of CNI (tacrolimus or cyclosporine [CsA]) over an 8-week period did not experience increased BPAR (10, 11) . Renal function was improved after CNI elimination in the PROTECT study based on estimated GFR (eGFR) using the MDRD formula, but for creatinine clearance (CockcroftGault formula), there was no significant difference from controls (10) . A smaller third trial maintained patients on both everolimus and CsA to month 1 and then abruptly discontinued CsA; basiliximab induction was given, and oral steroids were mandatory to day 35 (12) . Results showed significantly higher eGFR than in CsAtreated controls without increased BPAR. Consequently, it appears that everolimus-based CNI-free immunosuppression can be achieved successfully after liver transplantation, but the optimal adjunctive regimen and the timing for CNI withdrawal are not clear. Notably, none of these studies administered concomitant MPA as part of the everolimus-based regimen.
SIMCER was a multicenter trial in which de novo liver transplant recipients were randomized at week 4 to everolimus with low-exposure tacrolimus, discontinued by month 4, or to a conventional tacrolimus regimen, all with MPA and the option of corticosteroid therapy. The aim of the study was to compare renal function between the two treatment groups based on the change in eGFR between randomization and week 24 after transplant.
Methods

Study design and conduct
SIMCER was a 6-mo, prospective, multicenter, randomized, open-label study in de novo liver transplant patients undertaken at 15 transplant centers in France during 2012 to 2015 (ClinicalTrials.gov identifier NCT01625377). The study protocol was approved by the French Health Products Safety Agency (Afssaps/ANSM) and the relevant institutional review board. Written informed consent was obtained from all participants.
Eligibility criteria
Patients aged ≥18 years who underwent a primary whole or split liver transplant from a deceased donor were eligible for enrollment at the time of transplant. Key exclusion criteria were multiple or previous organ transplantation, a non-heart-beating donor, transplantation due to autoimmune hepatitis, primary sclerosing cholangitis or primary biliary cholangitis, eGFR ≤30 mL/min per 1.73 m 2 , a-fetoprotein >1000 ng/mL in patients transplanted for hepatocellular carcinoma (13) , BMI (kg/m 2 ) ≥35, and severe uncontrolled hypercholesterolemia (>9 mmol/L) or hypertriglyceridemia (>8.5 mmol/L) in the 6 mo prior to transplantation. At the point of randomization, patients were randomized if they were receiving tacrolimus and enteric-coated mycophenolate sodium (EC-MPS) with or without steroids. Enrolled patients were not randomized if proteinuria was >0.8 g/ 24 h or the urinary protein/creatinine ratio was >50 mg/mmol; if they had experienced steroid-resistant rejection and/or severe BPAR (Banff 1997 score ≥7 [14] ) between screening and randomization; if total bilirubin was ≥5 times higher than the upper limit of normal and/or prothrombin time and/or factor V was <30%; if platelet count was <50 000/mm 3 , neutrophil count was <1000/mm 3 , or leukocyte count was <2000/mm 3 ; or if Doppler ultrasound showed thrombosis of the hepatic arteries, hepatic veins, portal veins, or inferior vena cava.
Immunosuppression and concomitant medication
Basiliximab induction (20 mg) was given on days 0 and 4. Between transplant and randomization, all patients received tacrolimus (starting on day 3-5 after transplant), targeting a trough concentration of 6-10 ng/mL, and EC-MPS at a dose of 720 mg twice a day (minimum dose 360 mg twice a day). Intravenous mycophenolate mofetil was permitted as necessary in the first 10 days after transplant until per os feeding was resumed. Intravenous and oral steroids could be given according to local practice.
Randomization was performed at week 4 after transplant using a validated, automated, interactive Web Response System with investigators notified of the treatment group after stratification according to hepatitis C virus (HCV) status (positive or negative) and eGFR at time of transplant (<60 or ≥60 mL/min per 1.73 m 2 [MDRD] ). Patients randomized to the everolimus regimen received an initial dose of 1 mg twice a day, adjusted to target a trough concentration of 6-10 ng/mL. The tacrolimus dose was reduced by 50% on initiation of everolimus, with a further 50% reduction after 4 weeks (i.e. week 8 after transplant). Tacrolimus was discontinued during week 12 after transplant (and not later than week 16) if the everolimus trough concentration was in the range 6-10 ng/mL; otherwise, study treatment was discontinued. Patients randomized to the control arm continued to receive tacrolimus to week 24 (trough concentration 6-10 ng/mL). All patients continued EC-MPS to week 24, with or without steroids ( Figure S1 ).
Cytomegalovirus (CMV) infection prophylaxis, administered according to local practice, was mandatory for a minimum of 3 mo if the recipient was CMV negative and the donor was CMV positive and was highly recommended in all cases unless both recipient and donor were CMVnegative. All patients received prophylaxis for Pneumocystis jirovecii infections according to local practice until month 3.
Study end points
The primary end point was the change in eGFR (abbreviated MDRD formula [15] ) between randomization and week 24 after transplant. The principal secondary end point was a composite end point of treatment failure from randomization to week 24 after transplant, defined as treated BPAR (rejection activity index [RAI] score >3), graft loss, or death.
Other secondary end points were any BPAR, BPAR RAI score >3, treated BPAR (any event or score >3), death, graft loss, and renal function assessed by eGFR (MDRD formula [15] ) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (16) , creatinine clearance (Cockcroft-Gault formula [17] ), serum creatinine, urinary protein/creatinine ratio, chronic kidney disease stage (Kidney Disease Outcomes Quality Initiative criteria [18] ), and requirement for dialysis. A graft biopsy was to be carried out if acute rejection was suspected and before or within 48 h of starting antirejection treatment, with results graded locally according to Banff 1997 scoring (14) . Safety was assessed by (serious) adverse events, particularly CMV infections, de novo cancer, recurrence of hepatocellular carcinoma or HCV, de novo diabetes mellitus (defined as fasting glycemia ≥1.26 g/L [7.0 mmol/L] and/or treatment with a hypoglycemic agent [19, 20] ), and early discontinuation of the study treatment.
Statistical analysis
The primary variable, change in eGFR between randomization and week 24, was assessed by an analysis of covariance model with treatment arm and stratification group at randomization as factors and the eGFR value at baseline as the covariable, with results presented as least squares (LS) means with 95% confidence interval (CI) values for the difference between groups. The analysis was based on the intention-to-treat (ITT) population, using the last observation carried forward (LOCF) method for missing eGFR values at week 24.
The sample size calculation estimated that 205 patients would provide 80% power to detect a mean between-group difference of 10 mL/min per 1.73 m² (standard deviation [SD] 24 mL/min per 1.73 m²), based on published data (8), using a two-sided a level of 5% and allowing for a screening failure rate of 10% (i.e. 184 patients would be randomized).
The principal secondary end point, treatment failure, was compared between treatment groups using the v 2 test. The time from randomization to first treatment failure was described by a Kaplan-Meier analysis and compared between treatment arms using a log-rank test.
The ITT population included all randomized patients who received at least one dose of study treatment after randomization and for whom eGFR was available at randomization with at least one subsequent eGFR value.
The safety population included all randomized patients given at least one dose of study drug after randomization and who provided at least one posttreatment safety assessment.
Results
Patient population
In total, 241 patients were enrolled, of whom 188 (78%) were eligible for randomization at week 4 (93 everolimus, 95 tacrolimus) (Figure 1 ). The most frequent reason for randomization failure was not meeting randomization criteria (22 patients, including 15 in whom proteinuria was >0.8 g/24 h or the urinary protein/creatinine ratio was >50 mg/mmol). Of the 188 randomized patients, 183 were included in the ITT population and 184 were included in the safety population. Overall, 22 of 93 patients (23.7%) in the everolimus group and seven of 95 patients (7.4%) in the tacrolimus group discontinued the study drug prematurely ( Figure 1 ).
Baseline characteristics were similar between groups (Table 1) .
Immunosuppression and concomitant medication
Mean everolimus trough concentration was below the target range (6-10 ng/mL) until week 16 after transplant when the mean level was 7.2 ng/mL (SD 3.5 ng/mL), remaining within range thereafter (7.7 ng/mL [SD 3.5 ng/ mL] at week 24) ( Figure S2A ). The proportion of patients with an everolimus trough level <6 ng/mL was in the range of 33. The proportions of everolimus-and tacrolimus-treated patients receiving antihypertensive therapy were 52.7% and 45.3%, respectively, at randomization and 41.9% and 45.3%, respectively, at month 6. For antidiabetic therapy, the respective proportions were 39.8% and 37.9% at randomization and 29.0% and 30.5% at month 6. The use of lipid-lowering therapy was low in both groups (6.5% and 2.1%, respectively, at randomization; 11.8% and 5.3%, respectively, at month 6).
Renal function
Observed mean eGFR (MDRD formula) was similar in the two treatment groups at randomization (91. In the everolimus group, no renal parameter changed significantly from randomization to week 24 (Table 2) . In contrast, patients in the tacrolimus group showed significant decreases in eGFR, creatinine clearance, and serum creatinine. Mean proteinuria remained stable in the everolimus group ( At week 24, 55.4%, 39.2%, and 5.4% of patients in the everolimus group had chronic kidney disease (CKD) stage 1, 2, and 3, respectively, compared with 27.9%, 39.5%, and 32.6% in the tacrolimus cohort (p < 0.001) (Figure 3) . No patient was classified as CKD stage 4 or 5 at week 24.
Efficacy
The incidence of the principal secondary end point, treatment failure (treated BPAR, graft loss or death) from randomization to week 24, was similar in both groups (everolimus 10.0%, tacrolimus 4.3%, p = 0.134) ( Table 3) . Kaplan-Meier estimates for freedom from treatment failure during this period were 89.0% in the everolimus group versus 95.5% in the tacrolimus group (log-rank p = 0.115).
The incidence of BPAR between randomization and week 24 was significantly higher in the everolimus cohort (10.0% [9 of 90] vs. 2.2% [2 of 93] in the tacrolimus group; p = 0.026); the incidence of treated BPAR was 8.9% (8 of 90) versus 2.2% (2 of 93) (p = 0.055). Severity was recorded in eight of the nine everolimustreated patients with BPAR and was mild in five of eight cases and moderate in three of eight cases (Table 3 ). In the five cases of mild BPAR (Banff grade I), everolimus was continued in three cases and the patient was given oral or bolus steroid therapy and was stopped in two cases (one patient restarted tacrolimus and BPAR was treated with oral steroids; subsequent immunosuppression was not reported in the second patient, who received bolus steroids). The three patients with moderate (Banff grade II) BPAR all discontinued everolimus (two restarted tacrolimus; information was unavailable for the third case) and received bolus steroid therapy. There were no severe episodes of BPAR in either group. The mean time from randomization to first BPAR was longer in the everolimus cohort (mean 80.4 [SD 42.1] days) than the tacrolimus arm (30.5 [SD 27.6] days). Use of steroid therapy at month 3 or 6 after transplant showed no association with the incidence of BPAR at month 6 in either treatment group.
Among the eight patients in the everolimus group who had treated BPAR (RAI >3), the mean everolimus concentration during the study was <4.46 ng/mL (the lowest concentration quartile) in five of seven patients (one moderate and four mild BPAR), was between 4.46 and 5.78 ng/mL (i.e. the second lowest concentration quartile) in two patients (one mild, one moderate BPAR), and was only within target range in one patient (mild BPAR).
One patient with BPAR in the everolimus group was not treated and was still alive with a functioning graft at the end of the study.
Between randomization and week 24, one tacrolimus-treated patient lost his graft due to hepatic vein thrombosis. There were two deaths: An everolimus-treated patient died from sliding syndrome, and a tacrolimus-treated patient died with the cause reported as sudden death.
Adverse events
One serious adverse event or more occurred in 46.7% and 29.8% of patients in the everolimus and tacrolimus groups, respectively. Cholestasis, hepatocellular injury, anemia, hypokalemia, dyslipidemia, and sepsis were more frequent in the everolimus arm, whereas diarrhea and renal failure were reported more often in the tacrolimus group (Table 4) . Hepatic artery thrombosis occurred in only one patient, starting 29 days before randomization (to the everolimus group), with no suspected relation to the study drug.
The incidence of adverse events with a suspected relation to everolimus was 45.6% (most frequently aphthous stomatitis, anemia, impaired healing, and peripheral edema), whereas 29.8% of patients in the tacrolimus group had one adverse event or more with a suspected relation to tacrolimus (most frequently renal failure, diarrhea, and tremor) (Table S1 ). Impaired healing was reported in four everolimus-treated patients (delayed wound healing (2), asymptomatic impaired healing of the biliary fistula, and severe poor wound healing), with a suspected relation to the study drug in each case.
The most frequent serious adverse events in the everolimus group were sepsis (n = 5), biliary anastomosis complication (n = 5), rejection (n = 5), and renal failure (n = 3). The cases of sepsis were related to biliary complications in three patients and to pulmonary infections in two patients; none were suspected to be related to the study drug. In the tacrolimus group, the most frequent serious adverse events were biliary stenosis (n = 4), renal failure (n = 4), diarrhea (n = 4), and rejection (n = 3).
CMV infection was reported in 17.8% and 11.7% of patients in the everolimus and tacrolimus groups, respectively. The incidence of de novo diabetes mellitus was similar between groups (everolimus 61.1%, tacrolimus 63.8%). One patient in the everolimus group was reported to have uterine leiomyoma during the study. There were no cases of hepatocellular carcinoma recurrence.
Sixteen patients in the everolimus group (17.8%) and three patients in the tacrolimus group (3.2%) discontinued the study drug due to adverse events. The only adverse events that led to discontinuation in more than one patient were acute rejection (four everolimus-treated Data shown as n (%).
patients), pancytopenia (one patient in each group), and impaired healing (two everolimus-treated patients).
Discussion
In this multicenter randomized trial, everolimus was introduced at 1 mo after liver transplantation with tacrolimus reduction and then discontinuation by month 3 in patients given basiliximab induction and MPA therapy. Under this regimen, renal function remained unchanged over the first 6 mo after transplant, in marked contrast to the decline in renal function observed in the tacrolimus-based control arm. The difference in eGFR by the end of the study was substantial (14.3 mL/min per 1.73 m 2 ), and although patients were followed only to week 24 after transplant, there was no suggestion that values in the two groups were set to converge subsequently. BPAR, however, was significantly more frequent in the CNI-free cohort although episodes were mild in more than half the cases, and the incidence (10.0%) was acceptable and substantially lower than reported for a CNI-free regimen of everolimus (9, 10) . No graft losses occurred. These two findings indicate that a CNI-free regimen combining everolimus with MPA is a promising approach that offers renal protection without compromising midterm liver graft function, with the caveat that the study was performed in a selected group of patients. Discontinuation due to adverse events occurred in %18% of everolimus-treated patients.
In contrast to the H2304 study (8) and the Spare-theNephron study of conversion to sirolimus (21) , the immunosuppressive protocols in both treatment arms included basiliximab induction. The ReSpECT study showed that inclusion of induction in a tacrolimus-based regimen improves renal function, with a trend toward lower rates of BPAR (22) . In the PROTECT study, inclusion of basiliximab induction combined with slower CNI withdrawal avoided an increase in rejection, but a renal benefit was less clear-cut than in our CNI-free cohort (10) . This may be due to the fact that half the everolimus-treated patients in PROTECT discontinued study medication, most often because of adverse events; those who continued the everolimusbased regimen showed better preservation of renal function. In the present study, inclusion of concomitant MPA permitted slightly lower levels of everolimus exposure than in the PROTECT trial (e.g. 7.7 ng/mL at month 6 compared with 9.3 ng/mL at month 8 in PROTECT [10] ), possibly contributing to the lower rate of discontinuation due to adverse events in our cohort (23.7%). Unlike PROTECT (10) , in which patients did not receive MPA, or H2304 (8), in which MPA was prohibited after randomization, MPA was also included in the tacrolimus control arm throughout the current study-an approach that is now common in clinical practice. When comparing outcomes between the two studies, however, it should be borne in mind that our population was followed only to month 6 after transplant, whereas PROTECT analyzed patients at month 12, and it is feasible that more patients would have discontinued in the subsequent 6 mo. In the Spare-the-Nephron trial, in which 293 liver transplant patients were randomized to remain on CNI or to switch to sirolimus (both with mycophenolate mofetil but without protocol-specified induction therapy) at weeks 4-12 after transplant (21) , results were generally similar to those seen in the present study. Renal function at 1 year was again significantly higher in the CNI-free cohort but with a higher rate of mild BPAR and more frequent discontinuation due to adverse events (21).
The postrandomization incidence of BPAR in the everolimus/MPA arm of our study (10.0%) was lower than in the everolimus monotherapy arm in either the PRO-TECT trial (17.7%) (10) or the H2304 study (26.4%) (9) . Again, the difference in follow-up times should be taken into account, but because most acute rejection episodes occur early after transplant, it seems reasonable to conclude that combined administration of everolimus with MPA was more effective than everolimus alone. Even with basiliximab induction and concomitant MPA, however, the rate of BPAR was significantly higher in the everolimus group, and three of the everolimus patients with treated BPAR experienced moderate rejection. Notably, six of these seven patients had a mean everolimus concentration below the minimum target of 6 ng/mL and five had concentrations <4.4 ng/mL, underscoring the need to maintain adequate everolimus exposure in this context to ensure immunosuppressive efficacy.
Similar proportions of patients in both groups discontinued steroid therapy by week 24, an important consideration in view of the long-term morbidity associated with chronic steroid administration.
Adverse events with a suspected relation to the study drug were more frequent with everolimus than tacrolimus, as was discontinuation due to adverse events. During the period of switch from CNI therapy to a CNI-free regimen, most patients in the everolimus group were receiving concurrent everolimus, MPA, and tacrolimus (with steroids in some cases), which may have contributed to this observation. The most common adverse event leading to discontinuation of everolimus was acute rejection, followed by impaired healing, neither of which are unexpected, although it is possible that with more experience, the events could have been managed without switching therapy. Sepsis, although occurring only in the everolimus group, was not attributed to the study drug. The incidences of neutropenia and thrombocytopenia were similar between groups, indicating that hematological tolerability of the everolimus/MPA regimen was not a concern. Proteinuria and the urine protein/creatinine ratio were both significantly higher under everolimus at the end of the study, consistent with results of the H2304 study (8) , but proteinuria reported as an adverse event was rare (2.2%). Use of lipid-lowering therapy was higher in the everolimus-treated cohort at month 6, as might be expected, given the known lipogenic profile of mTOR inhibitors.
The study benefited from randomization with appropriate stratification and a large number of participating centers. We recognize that the 6-mo duration of the study is a limitation. Because rejection episodes occur primarily in the first 6 mo after transplant and switch to another regimen is also more frequent during the first few months, data from the first 6 mo are highly relevant; however, longer follow-up is desirable to confirm whether the renal advantage for the CNI regimen is maintained. The study population is now being followed to 5 years after transplant in the observational CERTITUDE study, during which patients are assessed annually on the anniversary of transplantation and immunosuppression is at the investigators' discretion.
An important point to consider is that the study population excluded certain patient types at high risk for rejection (e.g. patients with autoimmune conditions, recipients of a previous transplant, or those with previous severe BPAR) or mTOR inhibitor-related adverse events (e.g. patients with BMI >35 or significant proteinuria), and the results do not necessarily apply in those groups. In addition, patients with severe kidney disease (eGFR ≤30 mL/min per 1.73 m 2 ) were excluded, and the study population had a mean Model of End-Stage Liver Disease (MELD) score in the range of 18-19 with good baseline renal function. A similar improvement in renal function may not be achieved in patients with a higher MELD score and substantially impaired renal function at the time of transplant.
In conclusion, results of the SIMCER study indicate that early introduction of everolimus with early stepwise withdrawal of CNI after liver transplantation, supported by induction therapy and concomitant MPA with or without steroids, may be a preferable strategy for achieving CNI-free therapy than everolimus with steroids alone. We observed a clinically relevant benefit for renal function versus a conventional CNI-based regimen in this selected population using this approach, but this advantage was achieved at the cost of significantly more mild or moderate episodes of BPAR in the CNI-free group between randomization and month 6, largely driven by everolimus underexposure, and a higher rate of study medication discontinuation due to adverse events. Inclusion of MPA in the CNI-free regimen, with appropriate everolimus exposure targeting trough levels >6 ng/mL, may improve the tolerance and efficacy of everolimus-based CNI-free therapy. These results suggest that a regimen combining adequate exposure to everolimus with MPA can be an alternative to conventional CNI-based regimens in selected patients. Longer follow-up studies are necessary to determine how sustainable the beneficial impact on renal function will be and whether such a combination favorably affects detrimental events after liver transplant, such as the development of de novo tumors or hepatocellular recurrence.
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